Aducanumab: evidence from clinical trial data and controversies

Alzheimer’s disease (AD) is the most common cause for dementia worldwide. Until recently, all approved treatments for AD were symptomatic and not disease modifying. On 7 June 2021, the US FDA approved aducanumab, a human IgG1 anti-Aβ monoclonal antibody selective for Aβ aggregates, as the first dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Tampi, Rajesh R, Forester, Brent P, Agronin, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2021
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491638/
https://www.ncbi.nlm.nih.gov/pubmed/34650610
http://dx.doi.org/10.7573/dic.2021-7-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491638/
https://www.ncbi.nlm.nih.gov/pubmed/34650610
http://dx.doi.org/10.7573/dic.2021-7-3

Ejemplares similares